SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) hosted the Approaches to Early-stage Malignancies, Driving to a Cure Industry Program during the 38^th Annual Meeting & Pre-Conference Programs on November 1, 2023. Available here are the presentation slides and video from “Session 2: Predictive Biomarkers and Surrogate Endpoints” as permitted by presenters.

Program Organizers

• Nicholas Botwood, MD – Bristol Myers Squibb

• Jane Anne Healy, MD, PhD – Merck Sharp & Dhome LLC
  

• Giovanni Melillo, MD – AstraZeneca

Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.

Program Description

The SITC 2023 Industry Program, “Approaches to Early-stage Malignancies, Driving to a Cure,” will advance the science and application of cancer immunotherapy by bringing together high-level experts to provide high-level perspective surrounding cancer immunotherapy for early-stage disease. The program will explore recent translational and clinical studies of immunotherapy in the perioperative setting and the knowledge gained from these studies, including the identification and validation of predictive biomarkers and the development of surrogate endpoints for clinical trials. The program will also address statistical and regulatory considerations when designing clinical trials of cancer immunotherapy in the perioperative setting. Armed with a deeper understanding of cancer immunotherapy as treatment for early-stage malignancies, attendees will be equipped to develop cancer immunotherapy-based treatment strategies that are cost-efficient, faster, safer, and more effective for patients.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Summarize recent updates in the use of cancer immunotherapies to treat early-stage disease, especially in the perioperative setting
•  Discuss predictive biomarkers and surrogate endpoints and their relevance to studies investigating cancer immunotherapy for early-stage disease
• Address specific statistical and regulatory considerations pertaining to clinical trials of immunotherapy for early-stage disease and explain how they affect trial design and/or interpretation of trial results

To view the entire program schedule (including presenter permission to post) please click here.